



EXPRESS MAIL NO. EV336651823US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Chen Chen et al.
Application No. : 10/650,474
Filed : August 28, 2003
For : CRF ANTAGONISTIC PYRAZOLO[4,3-B]PYRIDINES

Art Unit : 1626
Docket No. : 690068.589C1
Date : January 16, 2004

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:


In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached Form PTO-1449. This application is a continuation and relies, under 35 U.S.C. § 120, on the earlier filing date of prior Application No. 09/623,634, filed February 26, 2001, now U.S. Patent 6,613,777. The references listed on the attached Form PTO-1449 were submitted to and/or cited by the Patent and Trademark Office in this prior application and, therefore, are not required to be provided in this application. If the Examiner wishes, copies will be provided upon request. As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Applicants believe this Information Disclosure Statement has been timely filed, however, the Director is authorized to charge any fee due by way of this Information Disclosure Statement to our Deposit Account No. 19-1090.

Respectfully submitted,

Seed Intellectual Property Law Group PLLC



Karl R. Hermans
Registration No. 33,507

Enclosures:

Form PTO-1449

701 Fifth Avenue, Suite 6300
Seattle, Washington 98104-7092
Phone: (206) 622-4900
Fax: (206) 682-6031

C:\690068.589C1\429153_1.DOC



EXPRESS MAIL NO. EV336651823US

Sheet 1 of 1

FORM PTO-1449 (REV. 7-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 690068.589C1	APPLICATION NO. 10/650,474
				APPLICANTS Chen Chen et al.	
				FILING DATE August 28, 2003	GROUP ART UNIT 1626
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)					

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
	AB	0 239 191 A2	09/30/87	EP		
	AC	0 773 023 A1	05/14/97	EP		
	AD	0 778 277 A1	06/11/97	EP		
	AE	WO 94/13643	06/23/94	WIPO		
	AF	WO 94/13676	06/23/94	WIPO		
	AG	WO 94/13677	06/23/94	WIPO		
	AH	WO 95/10506	04/20/95	WIPO		
	AI	WO 95/33750	12/14/95	WIPO		
	AJ	WO 97/29109	08/14/97	WIPO		
	AK	WO 98/03510	01/29/98	WIPO		
	AL	WO 98/29413	07/09/98	WIPO		

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AM		Chorvat, R. et al., "Synthesis, Corticotropin-Releasing Factor Receptor Binding Affinity, and Pharmacokinetic Properties of Triazolo-, Imidazo--and Pyrrolopyrimidines and -Pyridines," <i>J. Med. Chem.</i> 42(5):833-848, March 1999.
AN		Christos, T. et al., "Corticotropin-Releasing Factor Antagonists," <i>Exp. Opin. Ther. Patents</i> 8(2):143-152, February 1998.
AO		Owens, M. et al., "Physiology and Pharmacology of Corticotropin-Releasing Factor," <i>Pharmacological Reviews</i> 43(4), January 1991.
AP		Wustrow, D. et al., "Pyrazolo '1,5-β-Pyrimidine CRF-1 Receptor Antagonists," <i>Bioorganic and Medicinal Chemistry Letters</i> 8(16):2067-2070, August 1998.

EXAMINER	DATE CONSIDERED
----------	-----------------

* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).